- The shares of the medical device company Inari Medical ( NASDAQ: NARI ) jumped on Tuesday morning after reporting better-than-expected revenue for 2022 and setting its 2023 outlook ahead of the consensus.
- Citing preliminary unaudited financials, Inari ( NARI ) projected $107M – $108M and $382.7M – $383.7M revenue for Q4 2022 and full year, indicating ~29% YoY and ~38% YoY growth at the midpoint, respectively.
- Wall Street analysts expected the company to report ~$99.1M and ~$374.8M in revenue for Q4 and 2022, respectively.
- Noting its expansion to more than 275 U.S. sales territories as of 2022 year-end, Inari ( NARI ) also issued its 2023 guidance indicating $470M – $480M for the full year revenue, better than the ~$450.8M in the consensus.
- Read why Seeking Alpha contributor Zach Bristow reiterated his Buy rating on Inari ( NARI ) in November despite the lackluster share price moves since his last publication.
For further details see:
Inari Medical gains as outlook exceeds forecasts